AKT1 and thyroid gland carcinoma: The compound triggers oxidative damage through ROS accumulation, synergizes cell cycle arrest with apoptosis, and interferes with the core node of the PI3K-Akt pathway, demonstrating potential to overcome thyroid cancer drug resistance.